After Natalizumab: Real-World Study Pits Two B-Cell Drugs Head to Head in Multiple Sclerosis
A retrospective real-world study from Milan's San Raffaele institute compares ocrelizumab and ofatumumab as successor therapies for multiple sclerosis patients ...
